重组人促红素治疗1例肿瘤相关性贫血分析

1例原发性支气管肺癌患者，入院行第4次化疗。入院后血常规提示存在中度贫血，基于前3次化疗后血红蛋白持续下降的情况，医生认为该患者目前不宜化疗。为确定贫血的治疗方案，医生咨询了临床药师，药师查阅文献后建议选用重组人促红素（recombinant human erythropoietin，rhEPO）治疗贫血，待血红蛋白升到80 g/L后，再开始化疗。患者在rhEPO联合铁剂治疗一周后，血红蛋白值升至81 g/L，顺利完成化疗，病情平稳出院。

Analysis of recombinant human erythropoietin in the treatment of one case of cancer-related anemia

A patient with primary bronchogenic carcinoma was admitted to our hospital for the fourth chemotherapy. His blood regular test showed that he got moderate anemia. Based on the situation that his hemoglobin level continues to decline after the ifrst three doses of chemotherapy, doctors believed that he might be not suitable for further chemotherapy currently. However, the doctor changed his idea after consulting the clinical pharmacist about establishing an appropriate treatment for anemia. The pharmacist, after a review of the literature, recommended doctors that the recombinant human erythropoietin (rhEPO) would be used and the chemotherapy could be started when his hemoglobin level rose to 80 g/L. The hemoglobin level of this patient increased to 81g/L after he was treated with rhEPO and iron for one week. Finally, the chemotherapy was ifnished and the patient had a stable condition and was discharged from our hospital.